The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study

This network meta-analysis study assessed the efficacy and safety of various monotherapies for alopecia areata, focusing on janus kinase inhibitors (JAKIs) such as deuruxolitinib, ritlecitinib, and baricitinib. The analysis included 14 trials and found that deuruxolitinib 12 mg twice daily for 24 weeks was the most effective treatment based on the Severity of Alopecia Tool (SALT) scores. Higher doses of JAKIs, like baricitinib 4 mg, were more effective than lower doses. The study provides high-quality evidence to guide clinical decision-making and update treatment guidelines for alopecia areata, although deuruxolitinib is not yet commercially available.